Moneycontrol PRO
you are here: HomeNewsWorld

Toyota misses April global production target due to COVID, parts shortage

The world's largest automaker by sales produced 692,259 vehicles last month, a 9.1% drop from the same month last year, and falling short of an earlier plan of making about 750,000 vehicles worldwide.

May 30, 2022 / 10:25 AM IST
Representative image

Representative image

Japan's Toyota Motor Corp on Monday said it missed its global production target for April as COVID-19 outbreaks and a parts shortage slowed its post-pandemic recovery.

The world's largest automaker by sales produced 692,259 vehicles last month, a 9.1% drop from the same month last year, and falling short of an earlier plan of making about 750,000 vehicles worldwide.

The numbers raise questions over the severity of the pandemic-hit supply chains and how the disruption will affect production in the coming months.

Toyota last week downgraded its global production plan for June to around 800,000 vehicles due to the impact of COVID-19 containment measures in China and signalled the possibility of lowering its full-year output plan of 9.7 million vehicles.

The automaker on Monday also said global sales dropped 11.1% in April versus the same month a year earlier to 763,708 vehicles. Domestic sales, excluding sales of units Daihatsu and Hino Motors Ltd, tumbled almost 17% to 103,143 vehicles.

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show
Reuters
first published: May 30, 2022 10:25 am